This study is testing a medication, called hydroxychloroquine (HCQ) to assess safety and effectiveness to prevent individuals at risk of type 1 diabetes from progressing to type 1 diabetes. HCQ is approved by the U.S. Food and Drug Administration as a treatment (not a cure) for malaria, lupus, and rheumatoid arthritis. It operates through several pathways, including as an anti-inflammatory. HCQ has been used for over 60 years, but has not previously been studied as a treatment to prevent T1D. This Study These researchers are recruiting 200 people who are at least 3 years old and test positive for 2 or more autoantibodies as part of TrialNet. 2/3s will get the drug and 1/3 will get a placebo and will be a control group. The study involves 5 visits in the first 6 months, then 1 visit every 6 months for the remainder of the study (about six years). The primary end point is the number of people who progress to having abnormal blood glucose numbers or to being diagnosed with type-1 diabetes. (The hope is that few people getting the treatment will make this progression, as compared to the placebo group.) The study started in Aug-2018 and they hope to finish in 2024. Prevention studies take a long time, because the onset of type-1 takes a long time, so the researchers need to wait a long time to see if fewer people get the disease. This trial is part of TrialNet and is being funded by JDRF. The study's web page is here: https://www.trialnet.org/our-research/prevention-studies/hydroxychloroquine-hcq This study is recruiting at several sites all over the US: Barbara Davis Center: Aurora, Colorado, United States, 80045 Contact: Betsy Burke 303-724-6766 Betsy.Burke@ucdenver.edu Principal Investigator: Andrea Steck, MD University of Florida: Gainesville, Florida, United States, 32610 Contact: Jennifer Hosford 352-294-5759 email@example.com Contact: Paula Towe 352-294-5761 firstname.lastname@example.org Principal Investigator: Desmond Schatz, MD University of Miami: Miami, Florida, United States, 33136 Contact: Della Matheson 305-243-3781 email@example.com Contact: Natalia Sanders-Branca 305-243-6616 firstname.lastname@example.org Principal Investigator: David Baidal, MD University of Pittsburgh: Pittsburgh, Pennsylvania, United States, 15224 Contact: David Groscost 412-692-7241 email@example.com Contact: Kelli Delallo 412-692-5210 firstname.lastname@example.org Principal Investigator: Dorothy Becker, MD Vanderbilt Eskind Diabetes Clinic: Nashville, Tennessee, United States, 37232 Contact: Brenna Dixon 615-337-9597 email@example.com Contact: Faith Brendle 615-936-8638 firstname.lastname@example.org Principal Investigator: William Russell, MD University of Texas Southwestern Recruiting Dallas, Texas, United States, 75390 Contact: Lauren Boyles 241-648-4717 email@example.com Principal Investigator: Philip Raskin, MD Benaroya Research Institute: Seattle, Washington, United States, 98101 Contact: Mary Ramey 206-342-6945 firstname.lastname@example.org Contact: Marli McCulloch-Olson 206-515-5239 Marli@benaroyaresearch.org Principal Investigator: Carla Greenbaum, MD Wikipedia on HCQ: https://en.wikipedia.org/wiki/Hydroxychloroquine Clinical Trial Registry: https://clinicaltrials.gov/ct2/show/NCT03428945 Case studies: * https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206615/ * https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3029247 Use in Type-2: * https://www.researchgate.net/publication/270282245_Ipca_gets_first_approval_for_HCQ_in_diabetes Joshua Levy http://cureresearch4type1diabetes.blogspot.com publicjoshualevy at gmail dot com All the views expressed here are those of Joshua Levy, and nothing here is official JDRF or JDCA news, views, policies or opinions. My daughter has type-1 diabetes and participates in clinical trials, which might be discussed here. My blog contains a more complete non-conflict of interest statement. Thanks to everyone who helps with the blog.